RELATIVITY-047 Update: Nivolumab / Relatlimab Provides Progression Free Survival (PFS) Benefit in Previously Untreated Advanced Melanoma

Rodrigo Arrangoiz MS, MD, FACS, FSSO
  • Key Points:
    • An updated analysis from RELATIVITY-047 trial:
      • After a median follow-up of 25.3 months continues to show a significant PFS benefit for the nivolumab / relatlimab combination over nivolumab alone in the first-line treatment of patients with unresectable or metastatic melanoma:
        • While no new safety findings were noted
    • Although investigators observed improvements in melanoma-specific survival and OS:
      • These did not meet the prespecified bar of significance
    • Analyses of outcomes with subsequent therapy suggested a continued benefit with nivolumab and relatlimab beyond initial treatment and first progression
  • The dual-checkpoint inhibitor combination of nivolumab and relatlimab continues to provide a significant efficacy benefit over nivolumab alone in patients with previously untreated unresectable or metastatic melanoma:
    • According to an update from the randomized, double-blind, phase 2/3 RELATIVITY-047 trial presented during the 2023 ASCO Annual Meeting
    • After a median follow-up of 25.3 months:
      • Nivolumab and relatlimab continued to demonstrate a consistent, significant improvement over nivolumab in progression-free survival (PFS; HR 0.81, 95% CI [0.67, 0.97]) and a trend toward improved overall survival (OS; HR 0.82, 95% CI [0.67, 1.02])
    • An exploratory analysis found a numerical improvement in melanoma-specific survival with nivolumab and relatlimab versus nivolumab (HR 0.77, 95% CI [0.61, 0.97])
      • This updated analysis confirms previous efficacy and safety data reported in the trial
#Arrangoiz #CancerSurgeon #SurgicalOncologist #Melanoma #SkinCancer #MountSinaiMedicalCenter #MSMC #Miami #Mexico
Unknown's avatar

Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO

My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida. I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016. Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida. Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.

Leave a comment